Aileron Therapeutics, Inc Garners $40,000,000 Series D Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8236efec-9d9d-45f4-9e7c-93dfda02f1dc&Preview=1
Date 6/8/2009
Company Name Aileron Therapeutics, Inc
Mailing Address 840 Memorial Drive, 2nd Floor Cambridge, MA 02139
Company Description Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs.
Proceeds Purposes Proceeds from the financing will be used to advance Aileron’s lead Stapled Peptide program toward clinical trials in 2010 and to further advance the Stapled Peptide platform and programs in oncology, immune/inflammation, metabolic disease, and infectious disease.